The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
UNITED KINGDOM MULTICENTRE ACAMPROSATE STUDY (UKMAS): A 6-MONTH PROSPECTIVE STUDY OF ACAMPROSATE VERSUS PLACEBO IN PREVENTING RELAPSE AFTER WITHDRAWAL FROM ALCOHOL
Abstract
A 6-month randomized controlled study of acamprosate versus placebo in preventing relapse following withdrawal from alcohol was undertaken in 20 centres throughout the UK. Patients diagnosed as alcohol-dependent and detoxified within the preceding 5 weeks were randomly assigned to treatment with either acamprosate (A) 666 mg three times/day or identical placebo (P). A total of 664 patients were screened; 581 were entered into the treatment phase. One-third were episodic drinkers, 84% were male, 44% were unmarried and 48% were unemployed. Medication was first taken on average 24 days after the start of detoxification; 32% of patients had already relapsed by this time. The 6-month study period was completed by 35% of patients; adverse events led to withdrawal of a further 14% (A) and 9% (P) respectively. Compliance was poor in that, by the end of the second week, only 57% of patients were judged to be taking at least 90% of their tablets. The mean total of abstinent days achieved was 77 (A) and 81 (P). Complete abstinence for 6 months was achieved by 12% (A) and 11% (P); drinking remained within controlled limits in a further 3% (A) and 6% (P). An effect of acamprosate on consumption was not seen when subgroups, including those defined by the Lesch typology, were analysed separately. However, the mean percentage reduction in craving for alcohol measured on a visual analogue scale was greater in the acamprosate, than placebo, patients at week 2 and week 4 (P<0.001) and the mean decrease in the Hamilton Anxiety score at the 4th week was greater in the acamprosate than placebo patients (P = 0.017). In comparison with other published trials of acamprosate, patients started study medication after a longer time following detoxification, had more often recommenced drinking before medication was started and had a higher drop-out rate, and this might have contributed to the lack of a treatment effect in this study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
The disease concept of alcoholism.
Jellinek, E. M. (1960) · doi:10.1037/14090-000 · Cited by 1,335
Le Magnen, J., Tran, G., Durlach, J., & Martin, C. (1987) · Alcohol · doi:10.1016/0741-8329(87)90005-x · Cited by 97 · cited 1×
“…decreases postsynaptic potentials in the neocortex, perhaps by affecting excitatory amino acid (N-methyl-D-aspartate: NMDA) receptors (Zeise et al., 1993), and diminishes voluntary alcohol intake in alcohol-preferring rats (Boismare et al., 1984; Le Magnen et al., 1987a; Gewiss et al., 1991).”
Background
Cited by
Room, R., Babor, T., & Rehm, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17870-2 · Cited by 1,625
Jonas, D. E., Amick, H. R., Feltner, C., Bobashev, G., Thomas, K., Wines, R., Kim, M. M., Shanahan, E., Gass, C. E., Rowe, C. J., et al. (2014) · JAMA · doi:10.1001/jama.2014.3628 · Cited by 923
The clinical significance of drug craving
Tiffany, S. T., & Wray, J. M. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06298.x · Cited by 556
Carmen, B., Angeles, M., Ana, M., & María, A. J. (2004) · Addiction · doi:10.1111/j.1360-0443.2004.00763.x · Cited by 504
Maisel, N. C., Blodgett, J. C., Wilbourne, P. L., Humphreys, K., & Finney, J. W. (2013) · Addiction · doi:10.1111/j.1360-0443.2012.04054.x · Cited by 470
Acamprosate for alcohol dependence
Rösner, S., Hackl-Herrwerth, A., Leucht, S., Lehert, P., Vecchi, S., & Soyka, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004332.pub2 · Cited by 412
Kiefer, F., Jahn, H., Tarnaske, T., Helwig, H., Briken, P., Holzbach, R., Kämpf, P., Stracke, R., Baehr, M., Naber, D., et al. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.1.92 · Cited by 400
Efficacy of Naltrexone and Acamprosate for Alcoholism Treatment: A Meta‐Analysis
Kranzler, H. R., & Van Kirk, J. (2001) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2001.tb02356.x · Cited by 390
Neural Response to Alcohol Stimuli in Adolescents With Alcohol Use Disorder
Tapert, S. F., Cheung, E. H., Brown, G. G., Frank, L. R., Paulus, M. P., Schweinsburg, A. D., Meloy, M. J., & Brown, S. A. (2003) · Archives of General Psychiatry · doi:10.1001/archpsyc.60.7.727 · Cited by 378
Mann, K., Lehert, P., & Morgan, M. Y. (2004) · Alcoholism: Clinical and Experimental Research · doi:10.1097/01.alc.0000108656.81563.05 · Cited by 364
Lingford-Hughes, A., Welch, S., Peters, L., Nutt, D., & With expert reviewers (in alphabetical order): Ball D, B. N. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112444324 · Cited by 332
“This recommendation was influenced by the UK study which did not find acamprosate to be superior to placebo; this might have been due to the greater mean length of time after detoxification that acamprosate was started compared with other studies (Chick et al., 2000) (Ib).”
BackgroundResultChick, J. (2000) · Alcohol and Alcoholism · doi:10.1093/alcalc/35.6.587 · Cited by 310
Self-citationRösner, S., Leucht, S., Lehert, P., & Soyka, M. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881107078308 · Cited by 300
Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis
McPheeters, M., O’Connor, E. A., Riley, S., Kennedy, S. M., Voisin, C., Kuznacic, K., Coffey, C. P., Edlund, M. D., Bobashev, G., & Jonas, D. E. (2023) · JAMA · doi:10.1001/jama.2023.19761 · Cited by 285
Tiffany, S. T., Friedman, L., Greenfield, S. F., Hasin, D. S., & Jackson, R. (2012) · Addiction · doi:10.1111/j.1360-0443.2011.03581.x · Cited by 236
Neuroprotective and Abstinence-Promoting Effects of Acamprosate: Elucidating the Mechanism of Action
De Witte, P., Littleton, J., Parot, P., & Koob, G. (2005) · CNS Drugs · doi:10.2165/00023210-200519060-00004 · Cited by 201
Klauss, J., Penido Pinheiro, L. C., Silva Merlo, B. L., Correia Santos, G. D. A., Fregni, F., Nitsche, M. A., & Miyuki Nakamura-Palacios, E. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000984 · Cited by 178
“%) of subjects that remained abstinent in the sham-tDCS group by the end of 6-mth follow-up in our study was similar to the that reported by Chick et al. (2000), in a multi-centre prospective study with 581 alcoholics investigating the preventive effects of acamprosate on relapse of the use of…”
ResultConceptual framework for the etiology of alcoholism: a “kindling”/stress hypothesis
Breese, G. R., Overstreet, D. H., & Knapp, D. J. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2016-2 · Cited by 167
Conceptualizing changes in behavior in intervention research: the range of possible changes model
De Los Reyes, A., & Kazdin, A. E. (2006) · Psychological Review · doi:10.1037/0033-295x.113.3.554 · Cited by 172
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
The COMBINE Study Research Group (2003) · Alcoholism: Clinical and Experimental Research · doi:10.1111/j.1530-0277.2003.tb02873.x · Cited by 174
Mason, B. J. (2003) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2003.08.009 · Cited by 75
Tolliver, B. K., DeSantis, S. M., Brown, D. G., Prisciandaro, J. J., & Brady, K. T. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00973.x · Cited by 74
“However, a number of adequately powered negative trials of acamprosate have been reported (34, 43, 44), and even large meta-analyses that support the efficacy of acamprosate have reported modest effect sizes (40, 45, 46).”
Acamprosate: a review of its use in alcohol dependence
Plosker, G. L. (2015) · Drugs · doi:10.1007/s40265-015-0423-9 · Cited by 65
NETER ALCOHOLIC TYPOLOGY (NAT)a
CARDOSO, J. M. N., BARBOSA, A., ISMAIL, F., & POMBO, S. (2006) · Alcohol and Alcoholism · doi:10.1093/alcalc/agh247 · Cited by 55
Efficacy of acamprosate in the treatment of alcohol-dependent outpatients
Baltieri, D. A., & Andrade, A. G. D. (2003) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462003000300007 · Cited by 33
Guiraud, J., Addolorato, G., Aubin, H.-J., Batel, P., de Bejczy, A., Caputo, F., Goudriaan, A. E., Gual, A., Lesch, O., Maremmani, I., et al. (2021) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2021.06.003 · Cited by 20
Substance‐Related Disorders: Alcohol‐Related Disorders
Babor, T. F., Hernandez‐Avila, C. A., & Ungemack, J. A. (2015) · Psychiatry · doi:10.1002/9781118753378.ch72 · Cited by 8
Metadata
- Authors
- Chick, J.
- Venue
- Alcohol and Alcoholism
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-03-01
- Volume
- 35
- Issue
- 2
- Pages
- 176-187
- ISSN
- 0735-0414 (ISSN-L)
- 1464-3502
- OpenAlex
- W2099737019
- Cited by
- 213
- References
- 3
- FWCI
- 11.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.